Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line) [ID695]: Evaluation report part2
Table of contents
16. Manufacturer's submission - Celltrion
17. Manufacturer's submission - Merck Sharpe and Dohme (Remicade)
18. Manufacturer's submission - Merck Sharpe and Dohme (Simponi)
19. Consultee submission - British Society of Gastroentrology
20. Consultee submission - Crohn's Colitis United Kingdom
21. Consultee submission - Royal College of Nursing
22. Consultee submission - Royal College of Physicans
23. Clinical personal statement - Hawthorne
24. Clinical personal statement - Duncan
25. Patient personal statement - Byrne
26. Patient expert submission - Fitzgerald
27. Patient Access Scheme (PAS)
28. Additional - Patient Access Scheme - addendum
29. Additional factual response
30. Withdrawals due to lack of efficacy table
![Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line) [ID695]: Evaluation report part2](/proxy/?sourceUrl=http%3a%2f%2fwww.nice.org.uk%2fimages%2ficons%2fpdf.gif)
|
Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line) [ID695]: Evaluation report part2
23 September 2014 (10.06 Mb 1 sec) |
This page was last updated: 24 September 2014